Nimotop (nimodipine) is formulated to cross the blood-brain barrier more readily, making it effective for cerebral vasospasm, whereas most other dihydropyridine agents (e.g., amlodipine) are primarily used for systemic hypertension.
Yes, but because both lower blood pressure, your clinician may adjust doses or increase monitoring to avoid excessive hypotension.
The standard regimen is 30 mg every four hours for a total of 21 days, beginning as soon as possible after the subarachnoid haemorrhage.
Nimodipine is not a controlled substance and is not screened for in routine occupational or anti-doping tests, but athletes should disclose all medications to their governing bodies.
Sit or lie down immediately, avoid driving, and contact your healthcare provider. In cases of sudden, pronounced hypotension, seek emergency care.
There are no specific food bans, but grapefruit juice can inhibit CYP3A4 enzymes and may increase nimodipine levels; moderation is advised.
Nimodipine is generally avoided in pregnancy because safety data are insufficient. If the clinical situation is life-threatening, a specialist will weigh risks versus benefits.
Yes, nimodipine is also marketed as a generic tablet of the same strength; however, brand-name Nimotop is often prescribed for its established safety profile in neurosurgical settings.
Return them to a pharmacy waste collection box or follow the NHS guidelines for safe disposal of medicines; do not flush them down the toilet.
St John’s wort induces CYP3A4, which can lower nimodipine concentrations and reduce efficacy; discuss any supplement use with your doctor.
Nimotop is a brand-name medication that contains nimodipine as its active component. Nimodipine belongs to the dihydropyridine class of calcium-channel blockers and is formulated as a 30 mg oral pill. In the United Kingdom, Nimotop is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is most commonly prescribed to reduce the risk of cerebral vasospasm after a subarachnoid haemorrhage, a serious form of brain bleed.
Nimodipine blocks L-type voltage-gated calcium channels primarily in the smooth muscle of cerebral arteries. By inhibiting calcium influx, it relaxes these vessels, improving blood flow to the brain. The drug has a high affinity for the blood-brain barrier, allowing it to reach therapeutic concentrations within the central nervous system more readily than many other calcium-channel blockers.
This vasodilatory effect specifically targets the cerebral circulation, which is why Nimotop is effective in preventing the narrowing of brain arteries that can follow a subarachnoid haemorrhage.
Nimodipine is sometimes discussed in the context of hypertension and other vascular disorders, but these uses are not approved by the MHRA. Any off-label application should be considered only under specialist supervision.
Hypertension: Small clinical studies have explored nimodipine for blood-pressure control, particularly in patients who do not respond to other calcium-channel blockers. The evidence remains limited, and the drug is not licensed for this purpose in the UK.
Disclaimer: Off-label use requires careful medical supervision and an individualized risk-benefit assessment.
Migraine prophylaxis: A few observational reports suggest possible benefit, but robust randomized trials are lacking.
Because the supporting data are modest, clinicians typically reserve these approaches for research settings or highly selected patients.
If you are taking other medicines, supplements, or herbal products, always inform your healthcare provider before starting Nimotop.
This article provides educational information about Nimotop and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
